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Patients infected with herpes simplex virus 2 (HSV-2) have an increased risk of HIV-1 infection. In 
addition, HSV-2 reactivation in co-infected patients is associated with elevated plasma and genital 
HIV-1 levels as well as increased risk of HIV-1 transmission to HIV-negative partners.  Multiple trials 
have demonstrated that, on average, co-infected patients taking the anti-HSV medications acyclovir 
or valacyclovir experience a reduction in HIV-1 plasma viremia. However, it is unclear if this 
reduction in HIV-1 levels is an indirect effect attributable to decreased HSV-induced inflammation, or 
if the medication is directly inhibiting HIV-1 reverse transcription. In a recent report published in 
JAIDS, Drs. Tara Perti (University of Washington), Anna Wald (Vaccine and Infectious Disease 
Division), and their collaborators demonstrate that HIV-1 viremia was lower in patients treated with 
high-dose valacyclovir compared to standard dose acyclovir, even though valacyclovir had no 
additional effect on HSV-2 shedding in these patients. These data are consistent with previous 
studies suggesting that acyclovir and valacyclovir treatment may directly inhibit HIV-1 replication. 
To determine whether or not HSV-2 suppression is correlated with HIV-1 suppression, Perti, et al. 
treated 28 Seattle-area anti-retroviral therapy (ART) naïve patients co-infected with HIV-1 and HSV-
2. Patients were randomly assigned to one of two groups, receiving either the standard dose of 
acyclovir, or high-dose valacyclovir treatment for 12 weeks. After a two week washout period during 
which they received no drug, patients switched study arms, receiving the opposite treatment for 
another 12 weeks. HSV shedding was measured daily, while HIV-1 viremia was quantified weekly. A 
subset of patients also underwent more frequent HIV-1 testing at the initiation of valacyclovir 
treatment to determine the kinetics of HIV-1 decline. 
The team found that there was no difference in the amount of HSV-2 genital shedding (RR 0.95; 
95% CI 0.66-1.37; p=0.78), shedding episode duration (p=0.68), or quantity of HSV-2 DNA detected 
(p=0.67) when comparing the acyclovir- and valacyclovir-treated arms. Although they did not find a 
difference in HSV-2 suppression, the team found that HIV-1 RNA is lower in patients receiving high-
dose valacyclovir (0.27 log10 copies/mL, 95% CI -0.41 to -0.14 log10; p<0.001) compared to 
standard dose acyclovir. 
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In this study, the authors report a modest decrease in HIV-1 plasma viremia for patients treated with 
high-dose valacyclovir relative to acyclovir treatment. There was no difference in HSV-2 shedding 
between the two study arms; therefore, HSV-2 mediated inflammation is unlikely to account for the 
differences in HIV-1 viremia reported in this study. Taken together, these data suggest that 
valacyclovir may directly inhibit HIV-1 replication. “Further investigation is needed to determine 
if…high-dose valacyclovir, which is much less expensive than ART, could have a role in delaying 
HIV progression and decreasing HIV transmission for persons in developing countries who are not 
yet eligible for ART according to their national HIV treatment guidelines,” said Dr. Perti. 
Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret 
A, Corey L, Wald A. 2013. High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than 
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Difference in mean plasma HIV-1 RNA for each patient on high-dose 
valacyclovir versus standard-dose acyclovir. Each patient is represented by a 
bar. Blue bars are patients whose mean HIV-1 level was lower on high-dose 
valacyclovir, while gray bars are patients whose HIV-1 RNA level was lower 
on standard-dose acyclovir. 
